Search

Displaying results 8561 - 8570 of 10000 in total
  1. Drug

    Depatuxizumab

    go.drugbank.com/drugs/DB12826
    Investigational

    Depatuxizumab has been used in trials studying the treatment and diagnostic of Adenocarcinoma and Advanced Solid Tumors.

  2. Drug

    Robatumumab

    go.drugbank.com/drugs/DB12976
    Investigational

    Robatumumab has been used in trials studying the treatment of Osteosarcoma, Sarcoma, Ewing's, and Peripheral Neuroectodermal Tumor.

  3. Drug

    MK-4830

    go.drugbank.com/drugs/DB17454
    Investigational

    MK-4830 is a monoclonal antibody that targets the myeloid-specific immunoglobulin-like transcript (ILT) 4 receptor.

  4. Drug

    MEDI-491

    go.drugbank.com/drugs/DB17859
    Experimental

    MEDI-491 is a recombinant human parvovirus B19 vaccine composed of the VP1 and VP2 capsid proteins.

  5. Drug

    CEB-01

    go.drugbank.com/drugs/DB18505
    Investigational

    CEB-01 is a biocompatible polymeric PLGA nanofiber membrane containing the active substance 7-ethyl-10-hydroxycamptothecin

  6. Drug

    PARPI F-18

    go.drugbank.com/drugs/DB18657
    Experimental

    PARPI F-18 is a diagnostic agent under investigation for use in the management of glioblastoma multiforme.

  7. Drug

    Canvuparatide

    go.drugbank.com/drugs/DB18658
    Investigational

    Canvuparatide is a long-acting parathyroid hormone peptide prodrug under investigation for the treatment of hyperparathyroidism.[L48365]

  8. Drug

    Aminoflavone

    go.drugbank.com/drugs/DB19077
    Investigational

    Aminoflavone is under investigation in clinical trial NCT01015521 (Efficacy Study of Aminoflavone Prodrug to Treat Breast Cancer).

  9. Drug

    Echinomycin

    go.drugbank.com/drugs/DB15582
    Experimental

    Echinomycin is a cytotoxic polypeptide quinoxaline antibiotic isolated from _Streptomyces echinatus_ that binds to DNA and inhibits RNA synthesis.

  10. Drug

    BRG01

    go.drugbank.com/drugs/DB18173
    Investigational

    BRG01 is a genetically modified autologous CAR-T cell therapy under investigation for the treatment of nasopharyngeal carcinoma.[L48111]